Show simple item record

Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)

dc.contributor.authorAndronis, L
dc.contributor.authorGoranitis, I
dc.contributor.authorPirrie, S
dc.contributor.authorPope, A
dc.contributor.authorBarton, D
dc.contributor.authorCollins, S
dc.contributor.authorDaunton, A
dc.contributor.authorMcLaren, D
dc.contributor.authorO'Sullivan, JM
dc.contributor.authorParker, C
dc.contributor.authorPorfiri, E
dc.contributor.authorStaffurth, J
dc.contributor.authorStanley, A
dc.contributor.authorWylie, J
dc.contributor.authorBeesley, S
dc.contributor.authorBirtle, A
dc.contributor.authorBrown, JE
dc.contributor.authorChakraborti, P
dc.contributor.authorHussain, SA
dc.contributor.authorRussell, JM
dc.contributor.authorBillingham, LJ
dc.contributor.authorJames, ND
dc.date.accessioned2017-07-05T10:22:32Z
dc.date.issued2017-04-01
dc.identifierhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000396709600012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=d4b848928d1c3e5c86d298abb68475f9
dc.identifier.citationBJU INTERNATIONAL, 2017, 119 (4), pp. 522 - 529
dc.identifier.issn1464-4096
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/674
dc.identifier.eissn1464-410X
dc.identifier.doi10.1111/bju.13549
dc.format.extent522 - 529
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.subjectcastrate-refractory prostate cancer
dc.subjectcost-effectiveness analysis
dc.subjectquality of life
dc.subjectbone protecting treatments
dc.subjectzoledronic acid
dc.subjectSr89
dc.titleCost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)
dc.typeJournal Article
dcterms.dateAccepted2016-06-03
rioxxterms.versionofrecord10.1111/bju.13549
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2017-04
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBJU INTERNATIONAL
pubs.issue4
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Prostate and Bladder Cancer Research
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Prostate and Bladder Cancer Research
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume119
pubs.embargo.termsNot known
icr.researchteamProstate and Bladder Cancer Research
dc.contributor.icrauthorJames, Nicholas


Files in this item

Thumbnail
Name:
Cost-effectiveness of zoledronic ...
Size:
184.9Kb
Format:
PDF
Description:
Published version
View/Open

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0